查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889213

胸廓出口症候群 (TOS) 市場預測至 2032 年：按類型、病因、治療方法方法、手術入路、血管內治療、給藥途徑、最終用戶和地區分類的全球分析

Thoracic Outlet Syndrome (TOS) Market Forecasts to 2032 - Global Analysis By Type (Neurogenic TOS, Venous TOS, and Arterial TOS), Cause, Treatment Type, Surgical Approach, Endovascular Intervention, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球胸廓出口症候群 (TOS) 市場價值將達到 2.8625 億美元，到 2032 年將達到 23.2723 億美元，在預測期內的複合年成長率為 34.9%。

胸廓出口症候群（TOS）是指胸廓出口（鎖骨和第一肋骨之間的狹窄通道）內的神經和血管受到壓迫而引起的一系列疾病。這種壓迫會導致肩膀、手臂和手部出現疼痛、麻木和無力等症狀。 TOS通常由結構異常、重複性壓力、不良姿勢或頸部肩部損傷引起。

宣導和教育活動

教育計畫和宣傳宣傳活動正在提高早期症狀識別率，從而加快診斷和治療。醫學協會和倡導團體正積極推廣有關神經源性、靜脈性和動脈性胸廓出口症候群的知識。這種認知的提升鼓勵患者尋求專科治療，進而增加了對先進治療方法的需求。針對外科醫生和臨床醫生的培訓計畫正在提高診斷準確性和治療效果。隨著全球教育的擴展，市場正受益於患者參與度的提高和治療方法接受度的改善。

某些認證核可藥短缺

目前的治療方法通常依賴止痛藥、物理治療和手術干預，而非標靶藥物治療。缺乏特異性治療藥物限制了治療的個人化和長期管理方案的選擇。監管障礙進一步阻礙了胸廓出口症候群（TOS）新型藥物療法的研發。患者和臨床醫生常常對該領域藥物創新的缺乏感到失望。因此，對非藥物干預和侵入性手術的依賴限制了市場成長。

微創手術的技術進步

這些手術流程縮短了患者的復原時間，最大限度地減少了併發症，並改善了整體療效。機器人輔助手術和先進的影像引導等創新技術正在提高手術的精準度。醫院和診所正擴大採用這些技術，以滿足患者對更安全、更快速治療的需求。人工智慧驅動的手術規劃工具的整合進一步提高了手術效率。隨著微創手術的日益普及，它們正在為市場擴張和提高患者滿意度開闢新的途徑。

報銷政策不完善

許多醫療保健系統對外科手術和復健治療的報銷範圍有限。病人往往需要承擔高昂的自付費用，這常常阻礙他們接受先進的治療。保險公司在調整報銷機制以適應新技術和微創療法方面進展緩慢。這種經濟負擔限制了患者獲得治療的機會，尤其是在對醫療成本高度敏感的地區。如果沒有相應的報銷政策，創新治療方法的市場推廣可能會受到限制。

新冠疫情的影響：

新冠疫情擾亂了擇期手術，並延誤了胸廓出口症候群（TOS）患者的非緊急就診。封鎖措施和醫療系統不堪負荷導致診斷和治療被延後。然而，這場危機也加速了遠端醫療和遠距物理治療計畫的普及。醫療機構已開始優先考慮線上諮詢，以維持醫療服務的連續性。疫情後的策略強調在TOS管理中增強韌性、整合數位化資源以及建立靈活的治療路徑。儘管短期需求受到影響，但混合醫療模式的長期應用可望提振市場。

預計在預測期內，神經胸廓出口症候群細分市場將佔據最大的市場佔有率。

由於神經源性胸廓出口症候群（TOS）的盛行率高於靜脈型和動脈型TOS，預計在預測期內，神經源性TOS將佔據最大的市場佔有率。神經源性TOS患者常伴隨慢性疼痛和功能障礙，因此對治療的需求不斷增加。人們對該疾病的認知不斷提高，診斷技術的進步也推動了此症候群的檢出率。診所和醫院正加大對神經源性TOS的專項治療方法投入。研究活動也致力於改善針對該疾病的外科和非外科干預措施。

預計在預測期內，診所細分市場將呈現最高的複合年成長率。

預計在預測期內，診所板塊將達到最高成長率。病患數量的成長和對便利醫療服務需求的增加正推動診所拓展服務範圍。許多診所正在採用先進的診斷工具和微創技術來改善治療效果。提供個人化復健方案的能力也提升了患者的偏好。雲端基礎的患者管理系統有助於簡化工作流程並提高效率。

佔比最大的地區：

由於北美擁有先進的醫療基礎設施並積極採用創新外科技術，預計在預測期內將佔據最大的市場佔有率。患者和醫生較高的健康意識有助於早期診斷和治療。部分州優惠的報銷政策也促進了市場成長。美國和加拿大的主要醫院和研究機構正積極致力於研發新的治療方法。

複合年成長率最高的地區：

由於醫療基礎設施的不斷完善和外科技術投資的持續成長，預計亞太地區在預測期內將實現最高的複合年成長率。在中國、印度和日本等國家，人們對胸廓出口症候群（TOS）的認知度和診斷率都在不斷提高。政府為實現醫療體系現代化所採取的舉措，進一步推動了先進治療方法。全球和區域公司之間的策略聯盟正在促進醫療服務的可及性和技術的轉移。

免費客製化服務：

購買此報告的客戶可享有以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測，以及複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球胸廓出口症候群 (TOS) 市場（按類型分類）

  • 神經源性胸廓出口症候群
  • 靜脈性胸廓出口症候群
  • 動脈胸廓出口症候群

6. 全球胸廓出口症候群 (TOS) 市場（依病因分類）

  • 神經源性
  • 血管
  • 肌肉骨骼系統

7. 全球胸廓出口症候群 (TOS) 市場（依治療方法）

  • 保守治療
  • 手術治療
  • 藥物治療
  • 物理治療
  • 其他治療方法

8. 全球胸廓出口症候群 (TOS) 市場（以手術方式分類）

  • 腋窩入路
  • 鎖骨上入路
  • 經胸入路

9. 全球胸廓出口症候群 (TOS) 市場（依血管內治療分類）

  • 不等邊石塊
  • 支架置入術
  • 肋骨切除術
  • 血管成形術
  • 溶栓治療

10. 全球胸廓出口症候群 (TOS) 市場依給藥途徑分類

  • 口服
  • 腸外

11. 全球胸廓出口症候群 (TOS) 市場（依最終用戶分類）

  • 醫院
  • 診所
  • 診斷中心
  • 其他最終用戶

12. 全球胸廓出口症候群 (TOS) 市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第13章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第14章 企業概況

  • Pfizer Inc.
  • Amgen Inc.
  • Johnson &Johnson
  • Roche Holding AG
  • Novartis AG
  • Merck &Co., Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Bristol Myers Squibb
  • GlaxoSmithKline plc（GSK）
  • Takeda Pharmaceutical Company Limited
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc
Product Code: SMRC32673

According to Stratistics MRC, the Global Thoracic Outlet Syndrome (TOS) Market is accounted for $286.25 million in 2025 and is expected to reach $2327.23 million by 2032 growing at a CAGR of 34.9% during the forecast period. Thoracic Outlet Syndrome (TOS) refers to conditions that occur when nerves or blood vessels are compressed within the thoracic outlet, the narrow passage between the clavicle and first rib. This compression can cause symptoms such as pain, tingling, numbness, or reduced strength in the shoulders, arms, and hands. TOS often develops due to structural variations, repetitive strain, poor posture, or injuries involving the neck or shoulder area.

Market Dynamics:

Driver:

Increased awareness & education

Educational initiatives and awareness campaigns are helping individuals recognize early symptoms, leading to quicker diagnosis and treatment. Medical associations and advocacy groups are increasingly promoting knowledge about neurogenic, venous, and arterial TOS. This rising awareness is also encouraging patients to seek specialized care, boosting demand for advanced therapies. Training programs for surgeons and clinicians are improving diagnostic accuracy and procedural outcomes. As education spreads globally, the market benefits from stronger patient engagement and higher adoption of treatment options.

Restraint:

Lack of specific approved drugs

Current management often relies on pain medications, physiotherapy, and surgical interventions rather than targeted drugs. This lack of dedicated therapeutics restricts treatment personalization and long-term management options. Regulatory hurdles further slow the development of novel drug therapies for TOS. Patients and clinicians often face frustration due to limited pharmaceutical innovation in this area. Consequently, the market growth is restrained by dependence on non-drug interventions and invasive procedures.

Opportunity:

Technological advancements in minimally invasive surgery

The procedures reduce patient recovery time, minimize complications, and improve overall outcomes. Innovations such as robotic-assisted surgery and enhanced imaging guidance are making interventions more precise. Hospitals and clinics are increasingly adopting these technologies to meet patient demand for safer and faster treatments. The integration of AI-driven surgical planning tools is further enhancing procedural efficiency. As minimally invasive approaches gain traction, they open new avenues for market expansion and patient satisfaction.

Threat:

Inadequate reimbursement policies

Many healthcare systems provide limited coverage for surgical procedures and rehabilitation therapies. Patients often face high out-of-pocket expenses, discouraging them from pursuing advanced treatments. Insurance providers are slow to adapt reimbursement frameworks for newer technologies and minimally invasive approaches. This financial burden reduces accessibility, particularly in cost-sensitive regions. Without supportive reimbursement policies, market adoption of innovative therapies may remain restricted.

Covid-19 Impact:

The COVID-19 pandemic disrupted elective surgeries and delayed non-urgent consultations for TOS patients. Lockdowns and strained healthcare systems led to postponed diagnoses and treatments. However, the crisis accelerated the adoption of telemedicine and remote physiotherapy programs. Hospitals began prioritizing digital consultations to maintain continuity of care. Post-pandemic strategies now emphasize resilience, digital integration, and flexible treatment pathways for TOS management. While short-term demand was affected, long-term adoption of hybrid care models is expected to strengthen the market.

The neurogenic TOS segment is expected to be the largest during the forecast period

The neurogenic TOS segment is expected to account for the largest market share during the forecast period, due to its high prevalence compared to venous and arterial forms. Patients with neurogenic TOS often experience chronic pain and functional impairment, driving demand for treatment. Increased awareness and improved diagnostic techniques are leading to higher identification rates. Clinics and hospitals are investing in specialized therapies tailored to neurogenic cases. Research efforts are also focused on refining surgical and non-surgical interventions for this segment.

The clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the clinics segment is predicted to witness the highest growth rate. Rising patient volumes and demand for accessible care are encouraging clinics to expand services. Many clinics are adopting advanced diagnostic tools and minimally invasive techniques to improve outcomes. Their ability to provide personalized rehabilitation programs is also boosting patient preference. Cloud-based patient management systems are helping streamline workflows and enhance efficiency.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the region benefits from advanced healthcare infrastructure and strong adoption of innovative surgical techniques. High awareness levels among patients and physicians contribute to early diagnosis and treatment. Favorable reimbursement frameworks in certain states also support market growth. Leading hospitals and research institutions in the U.S. and Canada are actively engaged in developing new therapies.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to expanding healthcare infrastructure and rising investments in surgical technologies. Countries such as China, India, and Japan are witnessing increased awareness and diagnosis of TOS. Government initiatives to modernize healthcare systems are further supporting adoption of advanced treatments. Strategic collaborations between global and regional players are enhancing accessibility and technology transfer.

Key players in the market

Some of the key players in Thoracic Outlet Syndrome (TOS) Market include Pfizer Inc., Amgen Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Merck & Co Inc., AbbVie Inc., Eli Lilly and Co, Bayer AG, Bristol Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical, Sanofi S.A., Teva Pharmaceutical, and AstraZeneca.

Key Developments:

In November 2025, Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In November 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA(R) (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Types Covered:

  • Neurogenic TOS
  • Venous TOS
  • Arterial TOS

Causes Covered:

  • Neurogenic
  • Vascular
  • Musculoskeletal

Treatment Types Covered:

  • Conservative Treatment
  • Surgical Treatment
  • Medication
  • Physical Therapy
  • Other Treatment Types

Surgical Approaches Covered:

  • Transaxillary Approach
  • Supraclavicular Approach
  • Transthoracic Approach

Endovascular Interventions Covered:

  • Scalene Muscle Block
  • Stenting
  • Rib Resection
  • Angioplasty
  • Thrombolysis

Route of Administrations Covered:

  • Oral
  • Parenteral

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thoracic Outlet Syndrome (TOS) Market, By Type

  • 5.1 Introduction
  • 5.2 Neurogenic TOS
  • 5.3 Venous TOS
  • 5.4 Arterial TOS

6 Global Thoracic Outlet Syndrome (TOS) Market, By Cause

  • 6.1 Introduction
  • 6.2 Neurogenic
  • 6.3 Vascular
  • 6.4 Musculoskeletal

7 Global Thoracic Outlet Syndrome (TOS) Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Conservative Treatment
  • 7.3 Surgical Treatment
  • 7.4 Medication
  • 7.5 Physical Therapy
  • 7.6 Other Treatment Types

8 Global Thoracic Outlet Syndrome (TOS) Market, By Surgical Approach

  • 8.1 Introduction
  • 8.2 Transaxillary Approach
  • 8.3 Supraclavicular Approach
  • 8.4 Transthoracic Approach

9 Global Thoracic Outlet Syndrome (TOS) Market, By Endovascular Intervention

  • 9.1 Introduction
  • 9.2 Scalene Muscle Block
  • 9.3 Stenting
  • 9.4 Rib Resection
  • 9.5 Angioplasty
  • 9.6 Thrombolysis

10 Global Thoracic Outlet Syndrome (TOS) Market, By Route of Administration

  • 10.1 Introduction
  • 10.2 Oral
  • 10.3 Parenteral

11 Global Thoracic Outlet Syndrome (TOS) Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Clinics
  • 11.4 Diagnostic Centers
  • 11.5 Other End Users

12 Global Thoracic Outlet Syndrome (TOS) Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Pfizer Inc.
  • 14.2 Amgen Inc.
  • 14.3 Johnson & Johnson
  • 14.4 Roche Holding AG
  • 14.5 Novartis AG
  • 14.6 Merck & Co., Inc.
  • 14.7 AbbVie Inc.
  • 14.8 Eli Lilly and Company
  • 14.9 Bayer AG
  • 14.10 Bristol Myers Squibb
  • 14.11 GlaxoSmithKline plc (GSK)
  • 14.12 Takeda Pharmaceutical Company Limited
  • 14.13 Sanofi S.A.
  • 14.14 Teva Pharmaceutical Industries Ltd.
  • 14.15 AstraZeneca plc

List of Tables

  • Table 1 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Neurogenic TOS (2024-2032) ($MN)
  • Table 4 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Venous TOS (2024-2032) ($MN)
  • Table 5 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Arterial TOS (2024-2032) ($MN)
  • Table 6 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Cause (2024-2032) ($MN)
  • Table 7 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Neurogenic (2024-2032) ($MN)
  • Table 8 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Vascular (2024-2032) ($MN)
  • Table 9 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Musculoskeletal (2024-2032) ($MN)
  • Table 10 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 11 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Conservative Treatment (2024-2032) ($MN)
  • Table 12 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Surgical Treatment (2024-2032) ($MN)
  • Table 13 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Medication (2024-2032) ($MN)
  • Table 14 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Physical Therapy (2024-2032) ($MN)
  • Table 15 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 16 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Surgical Approach (2024-2032) ($MN)
  • Table 17 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Transaxillary Approach (2024-2032) ($MN)
  • Table 18 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Supraclavicular Approach (2024-2032) ($MN)
  • Table 19 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Transthoracic Approach (2024-2032) ($MN)
  • Table 20 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Endovascular Intervention (2024-2032) ($MN)
  • Table 21 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Scalene Muscle Block (2024-2032) ($MN)
  • Table 22 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Stenting (2024-2032) ($MN)
  • Table 23 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Rib Resection (2024-2032) ($MN)
  • Table 24 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Angioplasty (2024-2032) ($MN)
  • Table 25 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Thrombolysis (2024-2032) ($MN)
  • Table 26 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 27 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Oral (2024-2032) ($MN)
  • Table 28 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 29 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 31 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 32 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 33 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.